NVS vs the Top Picks average
| Pillar | NVS | Book avg | Diff |
|---|---|---|---|
| Quality | 0.87 | 0.84 | +0.03 |
| Growth | 0.68 | 0.87 | -0.19 |
| Value | 0.26 | 0.76 | -0.50 |
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
| 30-day change | -0.1% |
|---|---|
| 90-day change | -1.5% |
| Forward EPS estimate | $9.81 |
Over the last 90 days, what analysts expect NVS to earn is drifting lower (-1.5%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Novartis AG (NVS): score, valuation & FAQ
Novartis AG (NVS) is a Drug Manufacturers - General company that scores 53.4 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are FCF (A-) and P/E (B+), while PEG (D) rate weaker. On valuation, NVS sits about 4% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 7% annual free-cash-flow growth over the next decade.
Is NVS a good stock to buy?
Bull Rankings scores NVS 53.4 out of 100 on its quality-growth model, which is a middling reading. That is driven by FCF (A-) and P/E (B+). A score is a quantitative screen of Novartis AG's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does NVS score 53.4 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). NVS earns its highest marks on FCF (A-) and P/E (B+), and is held back by PEG (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is NVS overvalued or undervalued?
Based on $158.02, NVS sits about 4% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 7% annual free-cash-flow growth over the next decade. It trades at a 24.0x P/E (graded B+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in NVS?
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.